[1]ewsome P N, Sasso M, Deeks J J, et al. FibroScan-AST (FAST) score for the non-invasive identification of patients with non-alcoholic steatohepatitis with significant activity and fibrosis： a prospective derivation and global validation study[J]. The Lancet. Gastroenterology & Hepatology, 2020, 5(4)： 362–373.[2]Colognesi M, Gabbia D, De Martin S. Depression and Cognitive Impairment—Extrahepatic Manifestations of NAFLD and NASH[J]. Biomedicines, 2020, 8(7)： 229.[3]George E S, Sood S, Daly R M, et al. Is there an association between non-alcoholic fatty liver disease and cognitive function? A systematic review[J]. BMC Geriatrics, 2022, 22(1)： 47.[4]Seo S W, Gottesman R F, Clark J M, et al. Nonalcoholic fatty liver disease is associated with cognitive function in adults[J]. Neurology, 2016, 86(12)： 1136–1142.[5]Celikbilek A, Celikbilek M, Bozkurt G. Cognitive assessment of patients with nonalcoholic fatty liver disease[J]. European Journal of Gast-roenterology & Hepatology, 2018, 30(8)： 944–950.[6]Takahashi A, Kono S, Wada A, et al. Reduced brain activity in female patients with non-alcoholic fatty liver disease as measured by near-infrared spectroscopy[J]. K. Hashimoto. PLOS ONE, 2017, 12(4)： e0174169.[7]Weinstein A A, de Avila L, Paik J, et al. Cognitive Performance in Individuals With Non-Alcoholic Fatty Liver Disease and/or Type 2 Di-abetes Mellitus[J]. Psychosomatics, 2018, 59(6)： 567–574.[8]Felipo V, Urios A, Montesinos E, et al. Contribution of hyperammonemia and inflammatory factors to cognitive impairment in minimal heap-tic encephalopathy[J]. Metabolic Brain Disease, 2012, 27(1)： 51–58.[9]McAfoose J, Baune B T. Evidence for a cytokine model of cognitiv-e function[J]. Neuroscience & Biobehavioral Reviews, 2009, 33(3)： 355-366.[10]Yang Q, Zhou J. Neuroinflammation in the central nervous syste-m： Symphony of glial cells[J]. Glia, 2019, 67(6)： 1017–1035.[11]Balzano T, Forteza J, Borreda I, et al. Histological Features of Cerebellar Neuropathology in Patients With Alcoholic and Nonalcoholic Steatohepatitis[J]. Journal of Neuropathology & Experimental Neurology, 2018, 77(9)： 837–845.[12]Sun Y, Ma C, Sun H, et al. Metabolism： A Novel Shared Link between Diabetes Mellitus and Alzheimer’s Disease[J]. Journal of Diabetes Research, 2020, 2020： 1–12.[13]Bhalla S, Mehan S, Khan A, et al. Protective role of IGF-1 andGLP-1 signaling activation in neurological dysfunctions[J]. Neuroscience & Biobehavioral Reviews, 2022, 142： 104896.[14]Rose C F, Amodio P, Bajaj J S, et al. Hepatic encephalopathy： Novel insights into classification, pathophysiology and therapy[J]. Journal of Hepatology, 2020, 73(6)： 1526–1547.[15]Balzano T, Dadsetan S, Forteza J, et al. Chronic hyperammonemia induces peripheral inflammation that leads to cognitive impairment in rats： Reversed by anti-TNF-α treatment[J]. Journal of Hepatology, 2020, 73(3)： 582–592[16]Higarza S G, Arboleya S, Gueimonde M, et al. Neurobehavioral dysfunction in non-alcoholic steatohepatitis is associated with hyperammonemia, gut dysbiosis, and metabolic and functional brain regional deficits[J]. F. Reichmann. PLOS ONE, 2019, 14(9)： e0223019.[17]Mohammed S K, Magdy Y M, El-Waseef D AA, et al. Modulation of hippocampal TLR4/BDNF signal pathway using probiotics is a step closer towards treating cognitive impairment in NASH model[J]. Physiology & Behavior, 2020, 214： 112762.[18]Luo J, Wang T, Liang S, et al. Ingestion of Lactobacillus strain reduces anxiety and improves cognitive function in the hyperammonemia rat[J]. Science China Life Sciences, 2014, 57(3)： 327–335.[19]Li Z, Yi C-X, Katiraei S, et al. Butyrate reduces appetite and activates brown adipose tissue via the gut-brain neural circuit[J]. Gut, 2018, 67(7)： 1269–1279.[20]Labenz C, Huber Y, Michel M, et al. Nonalcoholic Fatty Liver Disease Increases the Risk of Anxiety and Depression[J]. Hepatology Communications, 2020, 4(9)： 1293–1301.
